HOSPITAL UNIVERSITARIO RUBER
Departament
University of California Los Angeles
Los Ángeles, Estados UnidosPublicacions en col·laboració amb investigadors/es de University of California Los Angeles (8)
2024
-
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2233-2244
2020
-
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
New England Journal of Medicine, Vol. 382, Núm. 7, pp. 610-621
2017
-
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 18, Núm. 7, pp. 904-916
-
The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug Delivery: Guidance for Improving Safety and Mitigating Risks
Neuromodulation, Vol. 20, Núm. 2, pp. 155-176
2016
-
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366
-
HERMIONE: A randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
BMC Cancer, Vol. 16, Núm. 1
2015
-
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial
The Lancet Oncology, Vol. 16, Núm. 16, pp. 1700-1710